Table. 2.

Liver transplantation cases

Study Type of cancer Before/after Allograft outcome Checkpoint inhibitor Year from tx to ICI IS regimen Cancer response Interval between IS reduction and ICI initiation ICI to rejection time
Tsung et al. (2021) [24] cSCC After No rejection Cemiplimab×2 NA Tac 1 mg PD NA
cSCC After No rejection Cemiplimab×12 NA Tac 0.5 mg NA NA
Qiu et al. (2020) [55] HCC Rec After No rejection Camrelizumab 4 Tac → sirolimus PR 2 yr
Zhuang et al. (2020) [56] HCC Rec After No rejection Nivolumab 2.7 Tac SD NA
Biondani et al. (2018) [57] LUSC After No rejection Nivolumab 13 Tac+MMF+Pred → Tac+everolimus+Pred SD 4 yr
DeLeon et al. (2018) [58] HCC Rec After No rejection Nivolumab×3 2.7 Tac PD NA
Melanoma After No rejection Pembrolizumab×2 5.5 Everolimus, MMF CR NA
HCC Rec After No rejection Nivolumab×4 7.8 Sirolimus, MMF PD NA
HCC Rec After No rejection Nivolumab×5 3.7 Tac PD NA
HCC Rec After No rejection Nivolumab×2 1.2 Tac NA NA
Melanoma After Acute rejection Nivolumab×2 1.1 Sirolimus NA NA 27 day
HCC Rec After Acute rejection Pembrolizumab×2 3.1 MMF, Pred NA NA 21 day
Gassmann et al. (2018) [59] HCC After Cellular rejection Nivolumab 3 Everolimus PD None 7 day
Kuo et al. (2018) [60] Melanoma After No rejection Ipilimumab then pembrolizumab 5 Tac+MMF+Pred → sirolimus+MMF PR 1 yr
Rammohan et al. (2018) [61] HCC After No rejection Pembrolizumab 3 Tac/sirolimus CR NA
De Toni et al. (2017) [62] HCC Rec After No rejection Nivolumab×15 1 Tac SD NA
Friend et al. (2017) [63] HCC Rec After Cellular rejection Nivolumab 4 Sirolimus 2 mg NA NA 17 day
HCC Rec After Cellular rejection Nivolumab 3 Tac 4 mg NA NA 7 day
Schvartsman et al. (2017) [64] Melanoma After No rejection Pembrolizumab 20 Tac CR NA
Varkaris et al. (2017) [65] HCC Rec After No rejection Pembrolizumab 8 Tac → 50% reduction dose PD NA
Morales et al. (2015) [66] Melanoma After No rejection Ipilimumab×4 8 Sirolimus 3 mg → 1 mg, MMF → off PR 3 mo
Ranganath et al. (2015) [67] Melanoma After No rejection Ipilimumab 8 Tac SD NA
Chen et al. (2021) [68] HCC Before Acute rejection Toripalimab×10 Tac, methylprednisolone PD None 10 hr
Dehghan et al. (2021) [69] HCC Before Acute rejection Nivolumab Tac, MMF, Pred Near CR None POD 10
Qiao et al. (2021) [70] HCC Before Rejection in 1/7 Pembrolizumab or camrelizumab Tac, MMF, methylprednisolone, Pred, etc. PR in 71% None POD 12 in one case
Tabrizian et al. (2021) [71] HCC Before Rejection in 1/9 (mild, low Tac level) Nivolumab Tac, MMF, Pred Near CR in 3/9 None NA
Nordness et al. (2020) [72] HCC Before Acute rejection Nivolumab Tac, MMF, Pred CR None POD 5
Schwacha-Eipper et al. (2020) [73] HCC Before No rejection Nivolumab NA PR None

tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; cSCC, cutaneous squamous cell carcinoma; NA, not applicable; Tac, tacrolimus; PD, progressive disease; HCC, hepatocellular carcinoma recurrence; Rec, recurrence; PR, partial response; SD, stable disease; LUSC, lung squamous cell carcinoma; MMF, mycophenolate mofetil; Pred, prednisone; CR, complete response; POD, postoperative day.

Korean J Transplant 2022;36:82~98 https://doi.org/10.4285/kjt.22.0013
© Korean J Transplant